Table 1. The Peak-to-Peak MEP Amplitudes Before and After Application of Sulpiride (SULP).
| Baseline 1 (mV) | Baseline 2 (mV) | Baseline 3 (mV) | MSO% | |
|---|---|---|---|---|
| Placebo | ||||
| iTBS | 1.03±0.10 | 1.05±0.10 | 1.07±0.06 | 46±2.4 |
| cTBS | 1.01±0.08 | 0.95±0.08 | 1.00±0.07 | 47±2.2 |
| 400 mg of SULP | ||||
| iTBS | 1.14±0.10 | 0.92±0.07 | 1.10±0.10 | 46±2.0 |
| cTBS | 0.98±0.11 | 0.95±0.08 | 0.95±0.05 | 45±1.6 |
Shown are the mean MEP amplitudes±SEM of baselines 1, 2, and 3, and the mean±SEM of the intensities of the magnetic cortical stimulus as percentage of maximum stimulator output (MSO). The intensity of TMS was adjusted to elicit MEPs with a peak-to-peak amplitude of on average 1 mV (baseline 1). At 1.5 h after intake of SULP (400 mg), a second baseline (baseline 2) was determined to control for an influence of the drug on cortical excitability, and adjusted if necessary (baseline 3). MEP amplitudes and percentage of MSO did not differ significantly between TBS conditions as well as before and after drug intake within the specific TBS/drug combinations (p⩾0.05, Student's t-tests, paired, two-tailed).